115 related articles for article (PubMed ID: 38559055)
1. CD40 is an immune checkpoint regulator that potentiates myocardial inflammation through activation and expansion of CCR2
Jimenez J; Amrute J; Ma P; Wang X; Dai R; Lavine KJ
bioRxiv; 2024 Mar; ():. PubMed ID: 38559055
[TBL] [Abstract][Full Text] [Related]
2. Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.
Ma P; Liu J; Qin J; Lai L; Heo GS; Luehmann H; Sultan D; Bredemeyer A; Bajapa G; Feng G; Jimenez J; He R; Parks A; Amrute J; Villanueva A; Liu Y; Lin CY; Mack M; Amancherla K; Moslehi J; Lavine KJ
Circulation; 2024 Jan; 149(1):48-66. PubMed ID: 37746718
[TBL] [Abstract][Full Text] [Related]
3. Expansion of Disease Specific Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.
Ma P; Liu J; Qin J; Lai L; Heo GS; Luehmann H; Sultan D; Bredemeyer A; Bajapa G; Feng G; Jimenez J; Parks A; Amrute J; Villanueva A; Liu Y; Lin CY; Mack M; Amancherla K; Moslehi J; Lavine KJ
bioRxiv; 2023 Apr; ():. PubMed ID: 37162929
[TBL] [Abstract][Full Text] [Related]
4. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
[TBL] [Abstract][Full Text] [Related]
5. Reprogramming macrophage by targeting VEGF and CD40 potentiates OX40 immunotherapy.
Liu Y; Ma Q; Yang K; Zhang D; Li F; Chen J; Zhou F; Wang H; Li N; Wang Y; Cao Y; Zhang C; Li X; Zhang H; Wang W; Li Y
Biochem Biophys Res Commun; 2024 Feb; 698():149546. PubMed ID: 38266314
[TBL] [Abstract][Full Text] [Related]
6. Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma.
Monteiro de Oliveira Novaes JA; Hirz T; Guijarro I; Nilsson M; Pisegna MA; Poteete A; Barsoumian HB; Fradette JJ; Chen LN; Gibbons DL; Tian X; Wang J; Myers JN; McArthur MJ; Bell D; William WN; Heymach JV
Cancer Prev Res (Phila); 2021 Mar; 14(3):313-324. PubMed ID: 33277316
[TBL] [Abstract][Full Text] [Related]
7. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
8. Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
Zhu H; Galdos FX; Lee D; Waliany S; Huang YV; Ryan J; Dang K; Neal JW; Wakelee HA; Reddy SA; Srinivas S; Lin LL; Witteles RM; Maecker HT; Davis MM; Nguyen PK; Wu SM
Circulation; 2022 Jul; 146(4):316-335. PubMed ID: 35762356
[TBL] [Abstract][Full Text] [Related]
9. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
10. Tissue Resident CCR2- and CCR2+ Cardiac Macrophages Differentially Orchestrate Monocyte Recruitment and Fate Specification Following Myocardial Injury.
Bajpai G; Bredemeyer A; Li W; Zaitsev K; Koenig AL; Lokshina I; Mohan J; Ivey B; Hsiao HM; Weinheimer C; Kovacs A; Epelman S; Artyomov M; Kreisel D; Lavine KJ
Circ Res; 2019 Jan; 124(2):263-278. PubMed ID: 30582448
[TBL] [Abstract][Full Text] [Related]
11. Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy.
Jacoberger-Foissac C; Blake SJ; Liu J; McDonald E; Triscott H; Nakamura K; Smyth MJ; Teng MW
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199513
[TBL] [Abstract][Full Text] [Related]
12. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
13. Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy.
Ben-Yehuda H; Arad M; Peralta Ramos JM; Sharon E; Castellani G; Ferrera S; Cahalon L; Colaiuta SP; Salame TM; Schwartz M
Mol Neurodegener; 2021 Jun; 16(1):39. PubMed ID: 34172073
[TBL] [Abstract][Full Text] [Related]
14. Blocking of programmed cell death-ligand 1 (PD-L1) expressed on endothelial cells promoted the recruitment of CD8
Li Q; Wei S; Li Y; Wu F; Qin X; Li Z; Li J; Chen C
Inflamm Res; 2023 Apr; 72(4):783-796. PubMed ID: 36867228
[TBL] [Abstract][Full Text] [Related]
15. Co-stimulatory agonists: An insight into the immunotherapy of cancer.
Pourakbari R; Hajizadeh F; Parhizkar F; Aghebati-Maleki A; Mansouri S; Aghebati-Maleki L
EXCLI J; 2021; 20():1055-1085. PubMed ID: 34267616
[TBL] [Abstract][Full Text] [Related]
16. CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner.
Leblond MM; Tillé L; Nassiri S; Gilfillan CB; Imbratta C; Schmittnaegel M; Ries CH; Speiser DE; Verdeil G
Cancer Immunol Res; 2020 Sep; 8(9):1180-1192. PubMed ID: 32661095
[TBL] [Abstract][Full Text] [Related]
17. The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells.
Merz C; Sykora J; Marschall V; Richards DM; Heinonen K; Redondo Müller M; Thiemann M; Schnyder T; Fricke H; Hill O; Gieffers C
J Immunother; 2018; 41(9):385-398. PubMed ID: 30273198
[TBL] [Abstract][Full Text] [Related]
18. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
19. CD4 T cells promote tissue inflammation via CD40 signaling without de novo activation in a murine model of liver ischemia/reperfusion injury.
Shen X; Wang Y; Gao F; Ren F; Busuttil RW; Kupiec-Weglinski JW; Zhai Y
Hepatology; 2009 Nov; 50(5):1537-46. PubMed ID: 19670423
[TBL] [Abstract][Full Text] [Related]
20. Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3.
Seko Y; Yagita H; Okumura K; Azuma M; Nagai R
Cardiovasc Res; 2007 Jul; 75(1):158-67. PubMed ID: 17434153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
